A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma
← catalyst calendarSponsored by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc (industry) · ZNTL — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
92actual
Sites
56
Countries
Australia, Canada, Georgia +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-07-28 | actual | When the study began enrolling |
| Primary completion | 2025-10-22 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-10-22 | actual | The whole study's end, after follow-up |
| First posted | 2021-03-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Uterine Serous Carcinoma
Intervention
- Drug: Azenosertib — also filed as ZN-c3
Primary outcomes
what the primary-completion date above is the date OFFrequency and severity of TEAEs
measured 2 years
Objective Response Rate as defined by the revised RECIST v1.1 as assessed by ICR
measured 2 years
Permalink · ZNTL's whole pipeline · Catalyst calendar · Every registered study · What changed